Feline Leukemia Virus Progressive Infection

Overview and Taxonomy of Feline Leukemia Virus Progressive Infection

Feline leukemia virus (FeLV) is an enveloped, single-stranded RNA virus belonging to the family Retroviridae, subfamily Orthoretrovirinae, and genus Gammaretrovirus [5, 11, 19]. This taxonomic placement is significant because gammaretroviruses are characterized by their ability to integrate into the host genome as a DNA provirus, a fundamental property that underpins the pathogenesis of persistent infections. FeLV is an exogenous retrovirus of domestic cats (Felis catus) and certain wild felids, distinct from the endogenous FeLV (enFeLV) elements that are stably integrated within the feline genome [9, 24, 26]. The exogenous virus is the one responsible for horizontal transmission and the development of progressive, often fatal, disease. The virus was first identified in the 1960s and has since become one of the most intensively studied animal retroviruses, serving as a natural model for retroviral pathogenesis, oncogenesis, and immunosuppression [11, 27].

The natural history of FeLV infection is remarkably heterogeneous, ranging from abortive infections in which the immune system eliminates the virus entirely, to progressive infections characterized by persistent viremia, high viral loads, and a high probability of FeLV-associated disease and premature death [5, 11, 13, 27]. The outcome of infection is determined by a complex interplay between host factors (age, immune competence, genetic background, endogenous retroviral elements) and viral factors (infectious dose, virus strain, subgroup) [9, 11, 18, 26]. The classification of infection outcomes has evolved substantially with the advent of more sensitive molecular diagnostic techniques. Four principal outcomes are now recognized: abortive infection, regressive infection, focal infection, and progressive infection [5, 13, 27]. Progressive infection, the focus of this chapter, represents the most clinically severe and epidemiologically relevant outcome.

Defining Progressive Infection

Progressive FeLV infection is defined as a persistent, systemic infection characterized by sustained p27 antigenemia (detectable in blood by ELISA or other immunoassays), detectable proviral DNA in peripheral blood cells and bone marrow, and active viral RNA replication [2, 5, 10, 13]. Cats with progressive infection fail to mount an effective immune response to control viral replication, leading to a lifelong, productive infection with continuous shedding of infectious virus in saliva, nasal secretions, urine, and feces [11, 20]. This persistent viremia is the hallmark of progressive infection and is associated with a grave prognosis. In a landmark prospective study from Brazil, the median survival time following diagnosis of progressive FeLV infection was a mere 30 days [1]; cats with regressive infection, in contrast, did not reach a median survival time during the study period, demonstrating a stark divergence in life expectancy. The World Organisation for Animal Health (WOAH) recognizes FeLV as a significant pathogen of domestic cats, and while not a zoonotic agent, the CDC and WHO acknowledge its importance in feline medicine and as a model for retroviral disease.

Molecular and Virological Taxonomy: Viral Subgroups

A critical facet of FeLV taxonomy and pathogenesis is the existence of multiple viral subgroups, defined by the sequence of the viral envelope glycoprotein (Env), which determines cell tropism and pathogenicity [4, 6, 11, 24]. The horizontally transmitted and primary subgroup is FeLV-A, which is present in all naturally infected cats. FeLV-A utilizes the thiamine transporter THTR1 as its cellular receptor and is capable of infecting a wide range of feline cells. It is considered the "mother" virus from which other subgroups arise through mutation or recombination.

FeLV-B arises de novo via recombination between FeLV-A and endogenous FeLV (enFeLV) sequences present in the domestic cat genome during the process of reverse transcription and integration [9, 24]. This recombination event replaces the 3' portion of the env gene of FeLV-A with homologous sequences from enFeLV, altering the receptor-binding domain. FeLV-B utilizes the phosphate transporter PiT1 as its receptor, which is expressed on a broader range of cells, including human cells in vitro [30]. The emergence of FeLV-B is a hallmark of progressive infection and is strongly associated with the development of neoplastic disease [4]. In studies from Brazil and Portugal, FeLV-B was detected in 54.5% to 68.8% of progressively infected cats, often in conjunction with lymphoma or leukemia [4, 6]. The presence of FeLV-B is indicative of a more advanced stage of infection and a higher proviral burden, as recombination events are more likely when viral replication is unchecked [9, 24].

FeLV-C is a highly pathogenic but less common subgroup that emerges through mutations in the env gene of FeLV-A, rather than recombination. FeLV-C utilizes the heme transporter FLVCR1 (feline leukemia virus subgroup C receptor) as a receptor [28]. The emergence of FeLV-C is specifically associated with the development of severe, non-regenerative anemia due to its ability to infect and suppress erythroid progenitor cells in the bone marrow [11, 12]. FeLV-C was, for instance, documented emerging in a cat that received a blood transfusion from a regressively infected donor, leading to fatal anemia [12]. FeLV-T is a T-cell-tropic subgroup that requires a co-receptor for entry and is associated with acute immunosuppression [11, 19]. The multiplicity of subgroups underscores the genetic plasticity of FeLV and its capacity for rapid adaptation within a single host, a key driver of its diverse clinical manifestations.

The Host-Virus Interface: Failure of Containment

The transition from exposure to progressive infection hinges on the inability of the host's immune system to contain the virus during the critical first few weeks post-exposure [11, 13]. Following oronasal inoculation (the primary natural route of transmission), the virus first replicates locally in lymphoid tissues of the oropharynx, then disseminates via infected lymphocytes and monocytes to distant lymphoid tissues, bone marrow, and epithelial tissues [11, 19]. In cats that will develop a regressive or abortive outcome, a robust humoral and cell-mediated immune response emerges, neutralizing the virus and suppressing viremia [11]. In contrast, cats destined for progressive infection mount a weak or ineffective immune response. This is characterized by a lack of neutralizing antibodies, a failure to generate a strong cytotoxic T lymphocyte (CTL) response, and the development of immunological tolerance to viral antigens in some cases [11, 17].

The bone marrow plays a central role in the establishment and maintenance of progressive infection [2, 8, 11, 13]. The virus infects hematopoietic stem cells and progenitor cells, establishing a permanent proviral reservoir. Once the bone marrow is infected, the cat is committed to a progressive outcome [2, 14, 16]. This infection of the bone marrow microenvironment is not merely a passive event; it actively contributes to the disease process. FeLV infects and suppresses bone marrow fibroblast colony-forming units (CFU-F), which are essential components of the hematopoietic stromal niche [14, 16]. This suppression, mediated in part by the viral envelope protein p15E [14], leads to a progressive decline in the supportive capacity of the marrow, contributing to the development of cytopenias. In a study of naturally infected cats with progressive disease, bone marrow aspiration and PCR revealed four distinct pathogenetic variants: a myeloproliferative variant (37.5%), a myelosuppressive variant (25%), a disassociated form (12.5%), and a subclinical carrier state (25%) [2]. This illustrates the direct impact of progressive FeLV infection on the hematopoietic system at the tissue level.

Epidemiological Context and Risk Factors for Progressive Infection

Globally, the prevalence of FeLV infection varies dramatically, with progressive infection being the most frequently diagnosed outcome in many regions. In southern Brazil and Chile, the prevalence of progressive infection (as defined by p27 antigen positivity and/or high proviral loads) has been reported at 34.4% and over 50%, respectively [3, 21]. A cross-sectional study in Brazil found that of 384 hospital cats, progressive infection was identified in 34.4% [3]. In Portugal, the overall FeLV prevalence was 11.3% in a 4.5-year study, with progressive infection accounting for a significant proportion of sick cats [22]. A multi-country European study reported progressive infection prevalence of 7.8% in Italy, 3.8% in Portugal, and 1.9% in both Germany and France [31]. These data indicate that while progressive infection is a global problem, its burden is disproportionately high in regions with large stray cat populations and lower vaccination rates. Stray and free-roaming cats are at the highest risk, serving as the primary reservoir for virus transmission [6, 7, 20]. A trap-neuter-return study in Switzerland identified geographically independent "hotspots" where up to 70% of stray cats tested positive for FeLV RNA, highlighting the explosive potential for transmission in unmanaged colonies [20].

Several host factors are strongly associated with an increased risk of developing a progressive outcome. Male cats are approximately three times more likely to be progressively infected than females, a finding attributed to behavioral factors such as increased territorial aggression and fighting, which facilitate virus transmission through bite wounds [3, 7, 9, 29]. Lack of vaccination against FeLV is the single most important modifiable risk factor, with odds ratios for infection ranging from 2.1 to 9.9 in various studies [6, 7, 21, 23]. Outdoor access is another critical risk factor, as it increases contact with potentially infected cats [7, 20]. Coinfection with other pathogens, particularly feline immunodeficiency virus (FIV), can exacerbate the risk and severity of FeLV infection. One study found that FIV-coinfected cats were 4.8 times more likely to have a regressive FeLV outcome, but the combination of both retroviruses generally leads to more profound immunosuppression [3, 15]. Coinfections with hemotropic mycoplasma (e.g., Mycoplasma haemofelis) are also frequent, likely due to the immunosuppressive state induced by FeLV [25]. Furthermore, the presence of the endogenous FeLV elements (enFeLV) has been shown to influence disease outcome; notably, higher enFeLV copy numbers are associated with a lower risk of progressive infection, suggesting a protective role of these endogenous elements, possibly through the action of small interfering RNAs [9, 26].

In summary, progressive FeLV infection is a distinct and devastating outcome of exposure to a gammaretrovirus that results from a failure of early immune containment, leading to persistent viremia, bone marrow infection, and a high risk of fatal neoplastic and degenerative diseases. The molecular taxonomy of the virus, particularly the emergence of recombinant subgroups like FeLV-B, and the interplay with host genetics and co-infections, define the clinical trajectory of the disease. Understanding the nuances of this outcome is essential for accurate diagnosis, realistic prognostication, and the development of effective prevention and therapeutic strategies.

Molecular Pathogenesis of FeLV Progressive Infection

The molecular pathogenesis of progressive feline leukemia virus (FeLV) infection represents a paradigm of retroviral-host interplay wherein the virus orchestrates a systematic dismantling of the feline hematopoietic and immune systems through a meticulously coordinated sequence of molecular events. Unlike abortive or regressive infections, which are characterized by effective host immune containment, progressive infection unfolds as a relentless trajectory toward persistent viremia, profound immunosuppression, bone marrow failure, and neoplastic transformation [11, 19]. Understanding the molecular underpinnings of this process requires a detailed examination of viral entry strategies, the establishment of proviral latency, subversion of innate and adaptive immune responses, and the specific molecular lesions that culminate in hematopoietic dyscrasias and malignancy.

Virological Determinants of Progressive Infection: Viral Subgroups and Cellular Entry

The molecular odyssey of progressive FeLV infection begins at the portal of entry, typically the oronasal mucosa, where the virus encounters its primary target: susceptible cells of the feline hemolymphatic system [11]. The viral envelope glycoprotein, specifically the surface unit (SU) encoded by the env gene, dictates host cell tropism and is the primary determinant of FeLV subgroup classification. Exogenous FeLV-A, the transmissible form that initiates nearly all natural infections, utilizes the thiamine transporter protein (THTR1) as its cellular receptor, a molecule ubiquitously expressed on feline cells [4, 24]. This broad tropism enables FeLV-A to establish a foothold in lymphoid tissues, initiating primary replication within local macrophages and lymphocytes within the first week post-exposure [19].

Critically, progressive infection is not merely a consequence of FeLV-A replication but is frequently propelled by the emergence of recombinant viral subgroups that arise de novo within the host. FeLV-B, the most clinically consequential recombinant, is generated through homologous recombination between exogenous FeLV-A and endogenous FeLV (enFeLV) elements integrated within the feline germline [24]. This recombination event, which occurs during reverse transcription, replaces the 3′ portion of the env gene with enFeLV-derived sequences, resulting in a virus that utilizes a different cellular receptor, the phosphate transporter Pit1 or Pit2, thereby expanding host cell range [24, 30]. The presence of FeLV-B is a hallmark of progressive infection; in one comprehensive study, 68.8% of cats with lymphoma and 70% of cats with leukemia harbored FeLV-AB dual infections, whereas FeLV-A alone was found in only a minority of cases [4]. This association is not coincidental: FeLV-B recombinants exhibit enhanced pathogenicity, likely due to their capacity to infect myeloid progenitor cells and stromal elements within the bone marrow microenvironment, a sanctuary that FeLV-A alone may access less efficiently [24].

A third subgroup, FeLV-C, emerges less frequently but with devastating specificity. FeLV-C arises from mutations in the env gene of FeLV-A and utilizes the feline leukemia virus subgroup C receptor (FLVCR1) for entry [28]. FLVCR1 is a heme export protein essential for erythroid maturation, and its receptor function is hijacked by FeLV-C, leading to a pure red cell aplasia [28]. The emergence of FeLV-C is a molecular traged: the virus not only infects erythroid progenitors but also disrupts heme homeostasis, contributing to the severe, non-regenerative anemia that is a cardinal feature of progressive infection [12, 16]. Studies have demonstrated that FeLV-C infection results in a profound suppression of bone marrow fibroblast colony-forming units (CFU-F), with reductions of 16–44% in progressor cats, indicating direct stromal damage that compromises the hematopoietic niche [14, 16].

Molecular Mechanisms of Immunosuppression and Hematopoietic Dysregulation

Once systemic dissemination is established, progressive FeLV infection is characterized by a sustained, high-level viremia that correlates with proviral DNA loads exceeding 1 × 10⁶ copies/mL of whole blood and p27 antigen concentrations above 30 ng/mL [10]. These molecular benchmarks differentiate progressive from regressive infection and presage the development of clinical disease. The virus’s primary assault is directed at the bone marrow, where it infects hematopoietic stem cells (HSCs), myeloid progenitors, and stromal cells, leading to a spectrum of hematological abnormalities [2, 32]. This infection is not cytolytic in the classical sense; rather, FeLV induces a state of myelodysplasia characterized by dysplastic changes in erythroid and myeloid precursors, aberrant maturation, and eventual cytopenia [2].

The molecular pathogenesis of FeLV-induced immunosuppression is multifactorial and exquisitely sophisticated. FeLV directly infects CD4+ and CD8+ T lymphocytes, B lymphocytes, macrophages, and dendritic cells, causing functional impairment that precedes frank cell death [19]. The virus dysregulates cytokine networks, promoting a shift toward an immunosuppressive cytokine milieu. Infected cats exhibit elevated levels of interleukin-10 (IL-10), a potent anti-inflammatory cytokine that inhibits T-cell proliferation and antigen presentation [15]. Concurrently, there is suppression of IL-12 and interferon-gamma (IFN-γ), cytokines critical for Th1-mediated antiviral responses. This molecular imbalance cripples the cell-mediated immune response, leaving the host vulnerable to opportunistic infections [15, 19].

A particularly insidious mechanism of immune subversion involves the viral envelope protein p15E, a transmembrane protein that exhibits immunosuppressive properties independent of viral replication. p15E has been shown to inhibit lymphocyte proliferation, suppress neutrophil chemotaxis, and modulate macrophage function [34]. The detection of p15E in follicular epithelial cells of cats with wavy whiskers, a novel clinical sign associated with FeLV infection, suggests that this protein may have paracrine effects on surrounding tissues, contributing to the diverse clinical manifestations of progressive infection [34].

At the bone marrow level, FeLV infection of stromal cells disrupts the hematopoietic microenvironment. The virus suppresses the formation of CFU-F, the mesenchymal progenitors that provide structural and trophic support for hematopoiesis [14, 16]. This suppression is mediated, at least in part, by the 15,000-dalton envelope protein, which, when incubated with bone marrow mononuclear cells in vitro, reduced CFU-F numbers to 21% of control levels [14]. The resulting stromal compromise leads to defective erythropoiesis, thrombopoiesis, and granulopoiesis, manifesting clinically as non-regenerative anemia (in 24.4–65.5% of progressive cases), thrombocytopenia (56.6%), and neutropenia (17.2%) [3, 32]. In one detailed retrospective analysis of cats with progressive FeLV confirmed by bone marrow PCR, four distinct pathogenetic variants were identified: a myeloproliferative variant characterized by hyperleukocytosis (37.5% of cases); a myelosuppressive variant with pancytopenia and myelodysplasia (25%); a subclinical carrier state with minimal peripheral blood changes (25%); and a dissociated form with discordant viral replication between blood and bone marrow (12.5%) [2]. This heterogeneity underscores the variability in molecular pathogenesis even within the progressive infection category.

Endogenous Retroviral Interactions and Epigenetic Modulation

A unique and increasingly recognized dimension of FeLV molecular pathogenesis involves the interplay between the exogenous virus and the endogenous FeLV (enFeLV) elements that comprise approximately 0.1% of the feline genome [9, 24]. enFeLV sequences are replication-defective proviruses stably inherited in the Felis lineage, and their role in progressive infection is paradoxical. On one hand, enFeLV provides the genetic substrate for recombination leading to FeLV-B, enhancing virulence [24]. On the other hand, higher enFeLV copy numbers have been associated with protection against progressive infection. In a natural epizootic within a breeding colony, male cats harbored higher enFeLV copy numbers and were more likely to have abortive or regressive outcomes, whereas females had lower enFeLV copy numbers and were disproportionately represented among progressive infections [9].

The mechanism underlying this protective effect may involve RNA interference. Lymphoid tissues, which are primary sites of FeLV replication, transcribe enFeLV-derived small interfering RNAs (siRNAs) and microRNAs (miRNAs) that can target exogenous FeLV transcripts [26]. Specifically, a 21-nucleotide miRNA transcribed from the enFeLV 5′ long terminal repeat (LTR) has been identified in the feline miRNAome, and its expression correlates with reduced permissiveness to exogenous FeLV infection in lymphoid cells [26]. This represents a form of host exaptation, where ancient retroviral remnants are repurposed as antiviral defenses.

At the epigenetic level, host cell bromodomain and extra-terminal domain (BET) proteins have been identified as critical cofactors for FeLV replication. BET proteins bind acetylated histones and facilitate the integration of the FeLV provirus into the host genome by tethering the viral integrase to chromatin [36]. Treatment of FeLV-infected cells with the BET inhibitor JQ1 results in a significant reduction in proviral load, total FeLV DNA, and p27 antigen production, with decreases in proviral integration documented in both fibroblast and lymphoma cell lines [36]. This discovery opens a potential therapeutic avenue, suggesting that pharmacological disruption of BET protein function could attenuate the establishment of progressive infection.

Molecular Pathways to Neoplastic Transformation

The oncogenic potential of FeLV is a direct consequence of its molecular architecture. FeLV is a replication-competent retrovirus that does not carry a classical oncogene; instead, it induces neoplasia through insertional mutagenesis, the integration of proviral DNA into or near host proto-oncogenes, leading to their dysregulated expression [19]. The long terminal repeat (LTR) sequences of FeLV contain potent enhancer and promoter elements that can drive transcription of adjacent cellular genes, and the specific LTR sequence variation influences both tissue tropism and oncogenic potential [11].

Lymphoma, particularly of T-cell origin, is the most common FeLV-associated neoplasm, with a 3.9-fold increased odds in FeLV-infected cats compared to uninfected counterparts [33]. The thymus is a frequent site of transformation, and experimental studies have mapped the disease-inducing capacity of specific FeLV strains to the LTR and env regions [11]. Lymphoma development is frequently accompanied by secondary leukemia, and the molecular signature of these neoplasms reflects the viral subgroup composition: FeLV-AB recombinants are overrepresented in both lymphoma and leukemia cases [4]. In a cohort of necropsied cats, the odds of leukemia were 19.4 times higher in FeLV-infected animals, underscoring the potent leukemogenic capacity of the virus [33].

Despite the high prevalence of FeLV infection in many global regions, with prevalence rates reaching 34.4% in Brazil [3], 54.95% in Chile [21], and 47.57% in some Chinese populations [35], the molecular events that determine whether an infection becomes progressive versus regressive remain incompletely understood. Factors such as the initial viral dose, host age, genetic background, and coinfection status modulate the early molecular dialogue between FeLV and the host immune system [11, 18]. Cats exposed to low viral doses may undergo an abortive infection characterized by seroconversion without detectable proviral DNA, whereas high-dose exposure overwhelms early immune defenses, permitting the establishment of proviral reservoirs in critical targets like bone marrow stem cells [13, 18]. The molecular pathogenesis of progressive FeLV infection is thus a multi-layered narrative of viral deception, host vulnerability, and molecular chaos that transforms the feline hematopoietic system from a bastion of immunity into a factory for viral propagation and malignant transformation.

Epidemiology of FeLV Progressive Infection

Feline leukemia virus (FeLV) progressive infection represents the most consequential and clinically devastating outcome of FeLV exposure, characterized by persistent viremia, sustained antigenemia, inexorable viral replication, and a markedly shortened lifespan. Understanding the epidemiology of this infection outcome is paramount for informing prevention strategies, guiding clinical prognostication, and allocating resources for veterinary public health interventions. The epidemiological landscape of progressive FeLV infection is a complex tapestry woven from geographic, demographic, behavioral, viral, and host genetic threads, each contributing to the observed patterns of disease occurrence, transmission dynamics, and population-level impact.

Global Prevalence and Geographic Distribution

The prevalence of FeLV progressive infection varies dramatically across global regions, reflecting differences in vaccination practices, cat population management, stray animal burdens, and socioeconomic factors. Southern Europe remains a significant hotspot, with Portugal exhibiting the highest documented prevalence in a 2019 Pan-European study at 8.8%, a figure that has since appeared to increase to 11.3% in a subsequent 4.5-year cross-sectional study in the Lisbon metropolitan area, with progressive infections comprising 47% of sick FeLV-infected cats [22]. Italy similarly demonstrates substantial progressive infection prevalence, with studies documenting 7.8% of tested cats exhibiting progressive outcomes, while Germany and France show markedly lower rates of 1.9% each, reflecting divergent regional vaccination uptake and stray cat management strategies [31].

The situation in Latin America is particularly alarming, with numerous studies documenting some of the highest global rates of progressive FeLV infection. A comprehensive study in southern Brazil revealed an overall FeLV prevalence of 45.6%, with progressive infections accounting for 34.4% of the study population, a figure that dwarfs European estimates [3]. This high prevalence is corroborated by multiple Brazilian investigations, with one urban population study in Caxias do Sul demonstrating a 30.6% overall infection rate, of which 65.5% of confirmed cases were progressive outcomes [7]. Chile presents similarly concerning epidemiology, with a recent study documenting a staggering 54.95% FeLV provirus prevalence in domestic cats, with non-vaccinated cats exhibiting significantly increased odds of infection [21]. These Latin American figures represent a public health crisis for companion animal welfare, driven by limited vaccination infrastructure, large stray populations, and insufficient diagnostic screening.

Asia presents a more heterogeneous picture. Studies from Southeast Asia and Taiwan revealed FeLV proviral DNA frequencies ranging from 0% in Indonesia to 18.5% in Thailand [40]. A separate investigation of healthy outdoor cats in Thailand documented a 4.2% FeLV antigen prevalence, suggesting lower but still significant circulation [23]. The variability across Asian nations likely reflects differences in sampling strategies, study populations (owned versus stray), and regional veterinary care access.

Risk Factors for Progressive Infection

The progression from FeLV exposure to persistent viremia and progressive infection is not random; rather, it is governed by a constellation of well-documented risk factors that operate at the host, agent, and environmental levels. Host demographic factors are among the most consistently identified determinants. Male cats are approximately three times more likely to develop progressive FeLV infection compared to females, a finding replicated across multiple independent studies [3, 9]. The mechanistic basis for this sex predisposition remains incompletely understood, though hormonal influences on immune function and behavioral differences leading to increased fighting and biting, and thus higher viral inoculum exposure, have been proposed. In a closed breeding colony experiencing natural FeLV epizootic, female cats were more likely to have progressive disease and FeLV-B emergence, suggesting that the interaction between sex and endogenous retroviral elements may also play a role [9].

Age at exposure constitutes another critical determinant of infection outcome. Young kittens are disproportionately susceptible to progressive infection, with FeLV-positive cats generally being younger than their FIV-positive counterparts; a study found that seven of eight FeLV-positive cats were between 1 and 5 years of age [45]. This age-dependent susceptibility is rooted in the ontogeny of the feline immune system; kittens possess immature adaptive immune responses that are less capable of mounting effective cytotoxic T-lymphocyte responses and neutralizing antibody production required to contain early viral replication in lymphoid tissues [11]. The early host-virus interactions during the first few weeks post-exposure are decisive, determining whether the virus or the cat will dominate the relationship, leading to either persistent viremia or a self-limiting, regressive infection [11].

Management and behavioral factors are powerful modulators of progressive infection risk. Cats with outdoor access face dramatically elevated risk, with odds ratios of 2.7 reported in Brazilian populations [7]. This association reflects increased opportunity for contact with infected conspecifics through biting, grooming, shared food bowls, and territorial disputes. FeLV is transmitted primarily through saliva, making aggressive interactions and communal living arrangements potent transmission vehicles. The lack of specific vaccination against FeLV confers an extraordinary odds ratio of 9.9 for infection [7], underscoring the profound protective efficacy of immunization when available and administered appropriately. The declining vaccination rates observed in some regions, such as Portugal where rates dropped from 14.2% to 5.0% over the study period, represent a concerning epidemiological trend that may portend resurgence of progressive infections [22].

Transmission Dynamics and the Role of Proviral Carriers

The transmission ecology of FeLV progressive infection is critically dependent on the shedding patterns of infected cats. Progressively infected cats are persistently viremic and shed high quantities of infectious virus in saliva, nasal secretions, urine, and feces, serving as the primary reservoir for horizontal transmission within feline populations [11, 17]. However, a more nuanced understanding of transmission dynamics has emerged with the recognition that regressively infected cats, those who have controlled viremia but harbor latent proviral DNA in bone marrow and other tissues, can under certain circumstances serve as infectious sources. Groundbreaking experimental work has demonstrated that blood transfusion from aviremic provirus carriers can transmit FeLV to naïve recipients, resulting in progressive infection, fatal FeLV-associated disease, and even evolution of FeLV-C variants causing non-regenerative anemia [12]. This finding has profound epidemiological implications, as regressive carriers may be unrecognized reservoirs capable of reactivating viremia and shedding virus when immunosuppressed or stressed. It also highlights the critical importance of screening blood donors not only for p27 antigen but also for proviral DNA using sensitive PCR methods [12, 43].

Viral load dynamics are intimately linked to transmission potential and infection outcome. Cats with high proviral DNA loads, typically exceeding 1 × 10⁶ copies/mL of whole blood, almost invariably have p27 antigen concentrations greater than 30 ng/mL in plasma and are classified as progressive infections [10]. Conversely, cats with proviral loads below this threshold have p27 concentrations less than 10 ng/mL and are more likely to have regressive or abortive outcomes [10]. This correlation between viral burden and infection outcome allows quantitative diagnostics to stratify cats by prognosis and transmission risk.

Coinfections and Viral Interactions

The epidemiological picture of FeLV progressive infection is complicated by frequent coinfections with other feline pathogens, which can modulate disease progression, clinical expression, and transmission dynamics. Coinfection with feline immunodeficiency virus (FIV) is particularly important; cats coinfected with FIV are 4.8 times more likely to belong to the FeLV regressive infection group, suggesting that FIV-induced immunosuppression may paradoxically alter the balance of FeLV containment in ways that are not yet fully understood [3]. However, the clinical consequences of FeLV/FIV coinfection are severe, with coinfected cats exhibiting significantly higher odds of bacterial diseases (OR 2.8) and neoplasia [33]. The immunological mechanisms underlying these interactions involve complex dysregulation of cytokine networks, with FeLV-positive cats showing lower IL-4 levels and higher IL-10 levels compared to retrovirus-negative controls [15].

Coinfection with feline foamy virus (FFV) is highly prevalent in FeLV-progressive cats, with 78% of FeLV-progressive cats having detectable buccal FFV DNA compared to only 22% of FeLV-regressive cats [38]. The directionality of this association may reflect FeLV-induced immunosuppression facilitating FFV replication and oral shedding, or alternatively, FFV infection may modulate the host immune response in ways that predispose to FeLV progression. FFV proviral load correlates positively with higher FeLV proviral and plasma viral loads, suggesting synergistic interactions between these retroviruses [9].

The interaction between FeLV and hemotropic mycoplasmas represents another dimension of coinfection epidemiology. In a study of cats in southern Brazil, 33.3% of Mycoplasma haemofelis-positive cats had concurrent FeLV infection, and male cats were at significantly higher risk for both infections [25]. The clinical synergy between these pathogens is evident in the exacerbation of anemia, with FeLV-induced bone marrow suppression compounding the hemolytic effects of mycoplasma infection.

Endogenous Retroviral Elements and Host Susceptibility

A fascinating and recently elucidated dimension of FeLV progressive infection epidemiology involves the role of endogenous feline leukemia virus (enFeLV) elements stably integrated within the domestic cat genome. These replication-defective proviral remnants represent a fossil record of ancient retroviral infections and have been exapted by the host to serve regulatory and defensive functions. Higher enFeLV copy numbers are associated with better FeLV disease outcomes, with male cats having higher enFeLV copy numbers and being more likely to have abortive FeLV disease, while females with lower enFeLV copy numbers are more prone to progressive infection and FeLV-B emergence [9]. The mechanism underlying this protection may involve RNA interference, as lymphoid-derived tissues that transcribe higher levels of enFeLV under basal conditions are less permissive to exogenous FeLV infection, and a 21-nucleotide microRNA transcribed from the enFeLV LTR has been identified in all feline miRNAomes examined [26].

Paradoxically, enFeLV also contributes genetic material to the generation of the highly virulent FeLV-B recombinant subgroup through recombination between exogenous FeLV-A envelope sequences and endogenous enFeLV elements during viral reverse transcription [24]. FeLV-B is predominantly generated de novo within each host, with more than half of infected cats harboring multiple unique FeLV-B variants [24]. The emergence of FeLV-B is associated with higher FeLV proviral and plasma viral loads, female sex, and progressive disease outcomes [9]. Phylogenetic analyses have confirmed that FeLV-A sequences are highly conserved across populations, while FeLV-B sequences diverge substantially and are similar to enFeLV, supporting a model where endogenous-exogenous recombination drives the emergence of pathogenic variants [4, 24].

Epidemiological Impact on Wild Felid Populations

The epidemiology of FeLV progressive infection extends beyond domestic cats to threaten wild felid populations, representing a significant conservation concern. The endangered Iberian lynx (Lynx pardinus) in southern Spain has been monitored for FeLV over 14 years, with overall proviral DNA prevalence in blood samples of 6.2% and in tissue samples of 10.2% [44]. While most infections in Iberian lynx appear to be regressive, suggesting that lynxes may control infection more effectively than domestic cats, the enzootic circulation of FeLV at low levels poses a constant threat, as only one viremic individual is needed to spark an outbreak capable of devastating a small, genetically depauperate population [44].

Progressive FeLV infection has been documented in captive jaguarundis (Puma yagouaroundi) in Brazilian zoos, with phylogenetic analysis revealing FeLV-A sequences most similar to FeLV-FAIDS and FeLV-3281 originally isolated from domestic cats in the United States, confirming cross-species transmission from domestic reservoirs [37]. More recently, fatal FeLV-associated enteritis was documented in a wild Eurasian lynx (Lynx lynx) in Germany, representing the first reported case of FeLV-associated enteritis in this species and highlighting the expanding host range of this virus [46]. The pathoepidemiological implications are profound: as human development encroaches on wild felid habitats and stray cat populations expand, the spillover risk of FeLV progressive infection into endangered wild populations increases correspondingly.

Temporal Trends and Diagnostic Implications

Longitudinal studies have revealed important temporal trends in FeLV progressive infection epidemiology. In Portugal, FeLV prevalence peaked at 14.1% in 2020, coinciding with the COVID-19 pandemic period when veterinary access and vaccination campaigns were disrupted [22]. The concurrent decline in vaccination rates from 14.2% to 5.0% over the study period suggests that pandemic-related disruptions may have long-lasting consequences for FeLV transmission dynamics. In Switzerland, FeLV RNA was detected in 4.0% of stray cat saliva samples, with three geographically independent hotspots exhibiting infection rates up to 70%, indicating that local pockets of intense transmission persist even in countries with generally low prevalence [20].

The accurate classification of infection outcome, progressive versus regressive versus abortive, requires sophisticated diagnostic algorithms that combine p27 antigen detection with proviral DNA PCR and, ideally, viral RNA quantification [8, 10, 13, 41]. Reliance solely on point-of-care antigen tests underestimates true prevalence by missing regressive and abortive infections, with studies showing that nested PCR can increase detection rates by up to 45.8% compared to rapid immunochromatographic assays [39]. The quantitative correlation between p27 antigen concentration and proviral DNA load (r = 0.761) provides a basis for using antigen concentration as a surrogate marker for infection outcome, with concentrations above 30 ng/mL strongly indicative of progressive infection [10]. Whole blood is the preferred sample type for antigen testing, as testing anticoagulated whole blood on point-of-care assays identified five and nine more low-positive FeLV-infected cats than plasma or serum, respectively [42].

Diagnostic Modalities for FeLV Progressive Infection: Serology, PCR, and Bone Marrow Analysis

The accurate and definitive diagnosis of progressive feline leukemia virus (FeLV) infection requires a sophisticated, multi-tiered diagnostic approach that transcends the simplistic binary of positive versus negative. The pathobiology of FeLV is characterized by a spectrum of infection outcomes, abortive, regressive, focal, and progressive, each with distinct virological, immunological, and clinical trajectories. The progressive outcome, defined by persistent p27 antigenemia, sustained proviral integration, and active viral replication, carries a grave prognosis, with median survival times as short as 30 days post-diagnosis in clinically affected cats [1]. Consequently, the diagnostic modalities employed must not only confirm the presence of the virus but must precisely stage the infection, quantify the viral burden, and assess the extent of bone marrow involvement. This section provides an exhaustive examination of the three pillars of progressive FeLV diagnosis: serological detection of the p27 antigen, molecular amplification of proviral DNA and viral RNA via polymerase chain reaction (PCR), and the critical, often underutilized, analysis of bone marrow.

Serological Detection of the p27 Core Antigen: The Frontline Diagnostic Assay

The cornerstone of initial FeLV screening is the detection of the viral p27 core antigen, typically performed using enzyme-linked immunosorbent assay (ELISA) or immunochromatographic point-of-care (PoC) tests. p27 is a highly conserved, abundant capsid protein that is shed into the cytoplasm of infected cells and released into the plasma, serum, and whole blood. The presence of this antigen in circulation is a hallmark of active viral replication and is the primary laboratory indicator of a progressive infection [3, 11].

The performance characteristics of PoC tests are highly variable and must be critically evaluated. A comparative study of three commercially available in-clinic tests (SNAP Feline Triple Test, WITNESS FeLV-FIV Test, and VetScan Feline FeLV/FIV Rapid Test) against a microtiter plate ELISA reference method demonstrated significant discrepancies in sensitivity. The SNAP test exhibited excellent agreement, detecting 98.0% of positive samples, while the WITNESS and VetScan tests showed markedly lower sensitivities of 79.0% and 73.0%, respectively [50]. While more recent iterations of PoC tests, such as the SNAP FIV/FeLV Combo Test, have reported near-perfect sensitivity (100%) and high specificity (99.2%) in some studies [51], the field performance of combined antigen-antibody tests (e.g., v-RetroFel®Ag/Ab) has been disappointing. In a large field study spanning Australia and Germany, this test failed to identify any regressive infections and correctly identified only 89-100% of progressive infections, but with a critical inability to differentiate infection outcomes [48]. This underscores a fundamental limitation of antigen testing alone: it cannot distinguish between a progressive infection with high-level antigenemia and a regressive infection that has cleared antigenemia but harbors proviral DNA. Furthermore, the diagnostic sensitivity can be significantly influenced by the sample type. Testing anticoagulated whole blood on the SNAP test has been shown to identify more low-positive cats compared to testing plasma or serum, likely due to the presence of virus in the cellular components of blood [42, 43]. A low-positive result on antigen testing, often defined by p27 concentrations below a certain threshold, is clinically ambiguous. However, quantitative ELISA has revealed a significant positive correlation between p27 antigen concentration and proviral DNA load (r = 0.761, P < 0.0001). Samples with high proviral loads (≥1 × 10⁶ copies/mL) typically have p27 concentrations exceeding 30 ng/mL, whereas cats with low proviral DNA loads invariably have p27 concentrations below 10 ng/mL [10]. This correlation suggests that quantitative antigen testing can serve as an indirect proxy for viral burden, aiding in the initial discrimination between likely progressive (high antigen) and regressive or low-level progressive (low antigen) infections. Despite its utility as a screening tool, a positive p27 antigen test is not definitive for a progressive infection and must be confirmed and contextualized by molecular testing.

PCR-Based Diagnostics: Detection of Proviral DNA and Viral RNA

The advent of polymerase chain reaction (PCR) revolutionized FeLV diagnostics by enabling the direct detection of the viral genome, bypassing the reliance on active antigen production. PCR allows for the definitive identification of FeLV infection and is indispensable for staging the infection outcome.

Proviral DNA Detection by PCR and qPCR: The detection of proviral DNA, the integrated form of the viral genome in the host cell's chromosomes, is the most sensitive and specific method for confirming FeLV infection. PCR targeting conserved regions of the gag gene or the U3-long terminal repeat (LTR) region can detect exogenous FeLV proviral DNA in peripheral blood leukocytes even in the absence of detectable p27 antigen [3, 13]. This is the definitive method for identifying regressive infections, where the virus has established latency but viral replication and antigen production have ceased [3, 27]. The distinction between progressive and regressive infection is made possible by quantitative real-time PCR (qPCR). A proviral DNA load threshold of approximately 1 × 10⁶ copies/mL of whole blood has been proposed as a reliable discriminatory point. Cats with progressive infection typically exhibit proviral loads above this threshold, often exceeding 1 × 10⁶ to 1 × 10⁷ copies/mL, while cats with regressive infection usually have loads below 1 × 10⁶ copies/mL [6, 10, 42]. A comprehensive epidemiological study in four European countries (Italy, Portugal, Germany, France) utilized a combination of p27 ELISA and qPCR for proviral DNA to accurately categorize infection outcomes, revealing that regressive infections constitute a substantial proportion of the total infected population [31]. Further refinements in PCR technology, such as nested recombinase polymerase amplification (nRPA), offer a rapid, isothermal alternative to traditional PCR. In one study, nRPA increased the detection rate in regressive cats by 45.8% compared to rapid immunochromatographic antigen testing, demonstrating its utility in low-resource settings [39].

Viral RNA Detection by RT-PCR and RT-qPCR: While proviral DNA indicates the presence of the virus in a latent or active state, the detection of viral RNA is a direct marker of active viral transcription and replication. Reverse transcription PCR (RT-PCR), often performed on saliva samples or plasma, is a powerful tool for confirming active viremia and identifying shedding animals. A strong correlation exists between p27 antigenemia and plasma viral RNA loads [13]. High viral RNA loads are characteristic of progressive infections and are a major risk factor for transmission [20, 49]. The combined use of RT-qPCR (for RNA) and qPCR (for proviral DNA) in bone marrow aspirate has been proposed as the "gold standard" for confirming or excluding a progressive infection, particularly in diagnostically challenging cases [8]. This dual-molecular approach allows for the simultaneous assessment of the size of the cellular reservoir (proviral DNA) and the activity of viral replication (viral RNA), providing a comprehensive snapshot of the host-virus interaction.

Bone Marrow Analysis: The Definitive Arbiter of Progressive Infection

The bone marrow is the primary target organ and a critical sanctuary site for FeLV. The progression from a contained, regressive infection to a virulent, progressive infection is predicated on the virus successfully establishing a foothold in the bone marrow. Therefore, direct analysis of bone marrow is the most definitive diagnostic modality for characterizing the pathogenesis and severity of progressive FeLV infection.

Bone Marrow PCR for Proviral and Viral RNA: Routine blood-based PCR may yield false-negative results in cases of latent or focal infection, where the provirus is sequestered in bone marrow stem cells but absent from the peripheral circulation [8]. A combined PCR study of bone marrow aspirate for both proviral DNA and viral RNA is a highly informative diagnostic approach that allows for the verification of progressive infection and the identification of the specific pathogenetic variant of the disease course [2]. In a retrospective analysis of eight cats with confirmed progressive infection, four distinct pathogenetic variants were identified based on bone marrow findings: a myeloproliferative variant (37.5% of cases) characterized by leukemias with hyperleukocytosis; a myelosuppressive variant (25% of cases) manifesting as pancytopenia and myelodysplasia; a disassociated form (12.5% of cases) with discordant viral replication status between peripheral blood and bone marrow; and a subclinical carrier state (25% of cases) with minimal hematologic changes [2]. The ability to identify proviral DNA in bone marrow is also biologically and epidemiologically significant. A landmark study demonstrated that blood transfusion from aviremic, provirus-positive donor cats (harboring latent FeLV in bone marrow) could reactivate and transmit a progressive, fatal infection to naïve recipient cats [12]. This underscores that the bone marrow proviral reservoir is not merely a passive marker but a biologically active source of virus capable of recrudescence.

Bone Marrow Cytology and Histopathology: Beyond molecular diagnostics, the direct examination of bone marrow architecture provides critical prognostic and pathophysiological insights. FeLV induces profound stromal disruption. Experimental studies have shown that cats developing a progressive infection and anemia (progressor cats) exhibit a progressive and sustained decrease in bone marrow fibroblast colony-forming units (CFU-F), the precursors of the hematopoietic microenvironment. This suppression, ranging from 16% to 44% of pre-inoculation values, is evident as early as two weeks post-infection and is directly correlated with the development of non-regenerative anemia [14, 16]. The viral envelope protein p15E has been identified as a key mediator of this stromal suppression [14]. Bone marrow aspiration cytology is also essential for diagnosing the sequelae of progressive infection. It can reveal various forms of myelodysplasia, aplasia, and neoplastic infiltration characteristic of myeloid or lymphoid leukemias [2, 32]. Furthermore, it can distinguish between immune-mediated cytopenias (e.g., antibody-mediated destruction of myeloid precursors) and direct viral cytopathic effects. This distinction is clinically crucial, as immune-mediated neutropenia in FeLV-positive cats can be responsive to immunosuppressive therapy (e.g., prednisolone), while direct viral destruction carries a much graver prognosis [47]. The integration of bone marrow cytology with PCR results allows for a comprehensive pathogenetic classification that guides prognosis and management.

Clinical Spectrum and Hematological Abnormalities in Progressive FeLV Infection

The progressive outcome of feline leukemia virus infection represents the most virulent and ultimately fatal manifestation of host–virus interaction. In this state, the virus establishes a persistent, high-level viremia characterized by continuous shedding and systemic dissemination. This is not a monomorphic disease; rather, it encompasses a remarkably heterogeneous array of clinicopathological disorders that reflect the profound tropism of FeLV for cells of the hemolymphatic system. The clinical spectrum ranges from subtle, subclinical deterioration to fulminant neoplastic proliferation or complete bone marrow collapse. Understanding this spectrum is essential for accurate prognostication and clinical management.

The Clinical Landscape: From Neoplastic Transformation to Immunosuppressive Collapse

The clinical presentation of progressive FeLV infection is dominated by two principal pathological processes: oncogenesis and immunosuppression, often acting in concert. Neoplasia, particularly lymphoma, is among the most common and well-characterized manifestations. In a large cross-sectional study of cats with progressive infection, lymphoma was identified in 38.5% of cases, followed by leukemia in 17.9% [3]. These findings are corroborated by survival analysis from Brazil, where lymphoma and leukemia were the primary causes of death among progressively infected cats, alongside anemia and other diseases [1]. The relationship between viral subgroup and neoplastic phenotype is striking: phylogenetic analysis of cats with progressive infection revealed that 68.8% of those with lymphoma and 70% of those with leukemia harbored both FeLV-A and FeLV-B, with FeLV-B arising de novo through recombination with endogenous FeLV elements [4]. This recombination event, driven by the error-prone reverse transcriptase and the availability of endogenous templates, appears to confer enhanced pathogenic potential, underscoring the dynamic genomic plasticity of the virus within a single host [24].

Immunosuppression, however, is arguably the most pervasive consequence of progressive infection. The virus exerts a direct cytopathic effect on immune cells, disrupts cytokine networks, and impairs antigen presentation, leading to a state of profound immune dysfunction [19]. This immunosuppression predisposes cats to a wide range of secondary and opportunistic infections. Concomitant infections, including those with Mycoplasma haemofelis, Toxoplasma gondii, and feline foamy virus, are frequently documented [3, 25, 38]. In one study, 15.4% of progressively infected cats presented with concurrent infections, while feline chronic gingivostomatitis (FCGS), a painful, immune-mediated oral disease, was present in 3.8% of cases [3]. The synergistic pathological impact of co-infection is notable; for example, cats co-infected with FeLV and feline infectious peritonitis virus (FIP) exhibit a combination of hematological abnormalities, including macrocytic hypochromic anemia, thrombocytopenia, and monocytosis, along with biochemical evidence of hepatic and hepatobiliary dysfunction [52]. Furthermore, FeLV-positive cats with sporotrichosis demonstrate significantly higher levels of the immunosuppressive cytokine IL-10 and lower levels of IL-4 compared to retrovirus-negative cats, correlating with poorer general condition [15]. This interplay between retroviral suppression and secondary pathogens creates a vicious cycle that accelerates clinical decline.

A particularly distinctive but often overlooked clinical sign is the development of wavy whiskers. In a large case-control study, 89.3% of cats with wavy whiskers were serologically positive for FeLV, and immunohistochemistry confirmed the presence of viral antigens (p27, gp70, and p15E) within the follicular epithelium of sinus hairs [34]. This finding, while not pathognomonic, provides a readily observable clinical clue that warrants immediate diagnostic testing. Other notable clinical presentations include plasma cell pododermatitis, a condition characterized by swelling, softening, and ulceration of the paw pads, which has been documented in association with FeLV and FIV co-infection, with FeLV antigen detected immunohistochemically in pad biopsies [53].

Neurological and Hematopoietic System Involvement: Beyond the Bone Marrow

Although less common, neurological involvement represents a grave complication of progressive FeLV infection. A comprehensive study of FeLV-positive cats with clinical disorders identified neurological abnormalities in 20.69% of cases [32]. These can arise from neoplastic infiltration of the central nervous system, as seen in a case of cerebellar lymphoma with concurrent cerebellar cortical degeneration in an 8-month-old cat, where immunohistochemistry confirmed a B-cell immunophenotype [54]. Alternatively, neurological signs may result from paraneoplastic phenomena or direct viral effects.

The bone marrow is the central battleground in progressive FeLV infection. A landmark study utilizing bone marrow aspiration combined with PCR diagnostics identified four distinct pathogenetic variants of the disease course: the myeloproliferative variant (37.5% of cases), characterized by leukemias with hyperleukocytosis; the myelosuppressive variant (25% of cases), manifested by pancytopenia and signs of myelodysplasia; a disassociated form (12.5%) with discordant viral replication status between peripheral blood and bone marrow; and a subclinical carrier state (25% of cases) with minimal peripheral blood changes [2]. This classification is of immense practical value, as it provides a framework for predicting disease trajectory and tailoring monitoring protocols.

Hematological Abnormalities: A Spectrum of Cytopenias and Proliferative Disorders

The hematological footprint of progressive FeLV infection is both deep and broad, reflecting the virus’s capacity to either destroy or transform hematopoietic precursors. Anemia is the single most common hematological abnormality, reported in 65.5% of clinically affected cats in one study and 24.4% in another [3, 32]. Critically, this anemia is predominantly non-regenerative, occurring in 32.8% of progressively infected cats [3]. This non-regenerative character points to a central mechanism: direct viral suppression of erythroid progenitor cells, often compounded by myelophthisis from neoplastic infiltration. Experimental studies have demonstrated that cats developing persistent FeLV infection and anemia exhibit a progressive and profound suppression of bone marrow fibroblast colony-forming units (CFU-F), with counts falling to 16–44% of pre-inoculation values within 10 weeks [14]. This suppression is mediated, at least in part, by the viral envelope protein (p15E), as in vitro incubation of bone marrow mononuclear cells with this protein reduced CFU-F numbers to 21% of control levels [14].

Thrombocytopenia is nearly as prevalent as anemia. In large cohort studies, thrombocytopenia was observed in 56.6% of cats with progressive infection and 38.2% of those with regressive infection [3]. The platelet count was significantly lower in both infected groups compared to FeLV-negative controls, with the most severe reductions occurring in progressive cases [3, 32]. The mechanisms underlying thrombocytopenia are multifactorial, including immune-mediated destruction, direct viral impairment of megakaryocytopoiesis, and consumption in the context of disseminated intravascular coagulation or secondary infections.

Lymphopenia is a consistent and clinically significant finding, present in 33.6% of progressively infected cats [3]. This reflects not only the direct cytopathic effect of the virus on lymphocytes but also the disruption of lymphoid tissue architecture and the dysregulation of lymphocyte homeostasis [19]. Conversely, some cats may present with lymphocytosis or neutrophilia, particularly in the myeloproliferative variant where leukemic transformation drives hyperleukocytosis [2]. Neutropenia, while less common (17.24% in one study), can be profound and life-threatening [32]. Notably, in some cases, this neutropenia may have an immune-mediated component, as demonstrated by a report of steroid-responsive neutropenia in an FeLV-positive cat where bone marrow cytology was consistent with immune-mediated destruction of mature myeloid cells [47]. This observation is critical, as it introduces a therapeutic avenue, immunosuppressive doses of prednisolone, that can achieve complete hematological remission in a subset of cats, challenging the assumption that all FeLV-associated cytopenias are invariably irreversible.

The hematological differences between progressive and regressive infection are not merely quantitative but qualitative. While both groups exhibit lower medians for hemoglobin, packed cell volume, platelet count, lymphocytes, and eosinophils compared to controls, the magnitude of these changes is consistently more severe in progressive infection [3]. Furthermore, the median packed cell volume and band neutrophil count were significantly higher in the progressive group, suggesting a more pronounced inflammatory or stress response [3]. This differential hematological profile is a valuable diagnostic and prognostic tool.

Survival and Prognostic Implications

The clinical and hematological severity of progressive FeLV infection is directly reflected in survival outcomes. In a survival analysis of 176 cats, the median survival time following diagnosis of progressive infection was a mere 30 days [1]. The primary causes of death, lymphoma, leukemia, and anemia, underscore the centrality of bone marrow failure and neoplastic transformation in the terminal phase of disease. Importantly, the health status at the time of diagnosis (i.e., being clinically ill) was associated with a 4- to 5-fold increase in the hazard ratio for death [1]. This stark statistic emphasizes that the window for effective intervention is narrow and that early detection of hematological abnormalities before the onset of overt clinical illness may be the only opportunity to alter the disease trajectory. The World Organisation for Animal Health (WOAH) recognizes FeLV as a significant pathogen of domestic cats, and the high morbidity and mortality associated with progressive infection underscore the need for stringent surveillance and control measures. The ability to identify the pathogenetic variant, myeloproliferative versus myelosuppressive, through bone marrow analysis not only refines the prognosis but also guides the clinician toward a more rational, evidence-based monitoring strategy [2].

Prognostic Factors and Survival Analysis in Progressive FeLV Infection

The clinical trajectory of progressive feline leukemia virus (FeLV) infection is characterized by remarkable heterogeneity, yet the overarching prognosis remains guarded to poor. A critical synthesis of contemporary survival data reveals that the median survival time for cats diagnosed with progressive FeLV infection is alarmingly brief, with studies from Brazil documenting a median survival of merely 30 days following diagnosis [1]. This stark figure, however, belies a more nuanced reality: survival is profoundly modulated by a constellation of viral, host, and environmental factors that collectively define the clinical outcome. The prognostic landscape of progressive FeLV infection is not a monolithic endpoint but rather a dynamic interplay of viral load kinetics, hematological reserve, comorbid conditions, and host genetic architecture, each of which must be rigorously evaluated to inform clinical decision-making and owner counseling.

Survival Metrics and Temporal Trajectories

The seminal survival analysis conducted by Biezus et al. (2025) in a Brazilian population provides the most definitive contemporary benchmark for progressive FeLV infection. In a cohort of 116 progressively infected cats, the median survival time was 30 days, a value that was statistically and clinically distinct from both regressively infected cats (median not reached) and uninfected controls [1]. This survival disadvantage was quantified through Cox regression modeling, which demonstrated that cats classified as "sick" at the time of inclusion, combined with progressive infection status, experienced a 4- to 5-fold increase in the hazard ratio for death [1]. The primary causes of mortality in the progressive group were lymphoma, leukemia, anemia, and other FeLV-associated diseases, underscoring the direct oncologic and myelotoxic impact of persistent viral replication [1]. Critically, the health status at enrollment was a dominant predictor: cats presenting with clinical abnormalities at diagnosis had a markedly compressed survival trajectory compared to those identified through screening [1]. This observation has profound implications for clinical practice, suggesting that early diagnosis prior to the onset of overt clinical signs may confer a survival advantage, though prospective interventional data remain lacking.

Longitudinal data from the United States, however, introduce a critical caveat to the uniformly grim prognosis. In a prospective study of 127 FeLV p27 antigen-positive cats followed for up to eight years, Beall et al. (2025) identified a subset of "low positive" cats, defined by low p27 antigen concentrations and low proviral DNA loads, that exhibited dramatically improved survival. At the study's extended follow-up, low positive cats had not reached a median survival, with 66% (19/29) still alive, compared to only 2.2% (2/90) of high positive cats [42]. This finding is paradigm-shifting: it demonstrates that the term "progressive infection" encompasses a spectrum of viral burden, and that cats with lower viral set-points may enjoy extended survival that approaches that of uninfected cohorts. The use of anticoagulated whole blood for antigen testing, combined with quantitative PCR for proviral DNA, was essential in discriminating these prognostic subgroups [42]. From a mechanistic standpoint, this suggests that the host's ability to partially constrain viral replication, even without achieving viral clearance, may be sufficient to delay the onset of terminal FeLV-associated diseases.

Viral Load as the Central Prognostic Determinant

The quantitative relationship between viral burden and survival is perhaps the most robust and reproducible prognostic factor in progressive FeLV infection. Proviral DNA load and plasma p27 antigen concentration are directly correlated (r = 0.761, P < 0.0001), and both metrics stratify cats into clinically meaningful prognostic categories [10]. Samples with proviral loads of at least 1 × 10⁶ copies/mL of whole blood typically correspond to p27 antigen concentrations exceeding 30 ng/mL, and these cats are at the highest risk for rapid disease progression [10]. Conversely, proviral loads below this threshold are associated with p27 concentrations less than 10 ng/mL and a more indolent clinical course [10]. The mechanistic basis for this relationship is rooted in the fundamental biology of FeLV replication: high-level viral replication drives direct cytopathic damage to hematopoietic precursors, induces profound immunosuppression through dysregulation of cytokine networks and functional impairment of CD4⁺ and CD8⁺ T cells, and promotes neoplastic transformation via insertional mutagenesis and oncogene activation [11, 19]. Each of these pathogenic sequelae is dose-dependent, with higher viral loads accelerating the timeline to clinical decompensation.

The pathogenetic variants of progressive infection identified by Tsarkova et al. (2025) further refine the prognostic utility of viral load assessment. Through comprehensive bone marrow aspiration combined with PCR for proviral DNA and viral RNA, four distinct pathogenetic patterns emerged: myeloproliferative (37.5%), characterized by leukemias with hyperleukocytosis; myelosuppressive (25%), manifesting as pancytopenia and myelodysplasia; a dissociated form (12.5%) with discordant viral replication between peripheral blood and bone marrow; and a subclinical carrier state (25%) with minimal hematological changes [2]. Each of these variants carries a distinct prognosis. The myelosuppressive variant, with its attendant pancytopenia, is associated with the highest short-term mortality due to the compounded risks of anemia, thrombocytopenia-associated hemorrhage, and neutropenia-driven secondary infections. The myeloproliferative variant, while also grave, may permit a slightly longer survival window, particularly if cytoreductive therapy is pursued. The subclinical carrier state, despite being classified as progressive based on bone marrow proviral detection, may paradoxically be associated with prolonged survival if the bone marrow microenvironment exerts partial control over viral replication. The dissociated form introduces a unique prognostic challenge: discordance between peripheral blood and bone marrow viral status complicates risk stratification and suggests that a single compartment assessment may be insufficient for accurate prognostication [2, 8].

Hematological Profile as a Prognostic Window

The hematological landscape of progressive FeLV infection provides a readily accessible and highly informative prognostic tool. Anemia, particularly non-regenerative anemia, stands as the most prevalent hematological abnormality and a powerful negative prognostic indicator. In a study of FeLV-positive cats with clinical disorders, mucosal pallor, a clinical surrogate for anemia, was observed in 65.5% of cases, and anemia was documented in an equivalent proportion [32]. The pathogenesis of FeLV-associated anemia is multifactorial, encompassing direct viral suppression of erythroid precursors, myelophthisic displacement by neoplastic cells, immune-mediated hemolysis, and, in some cases, the emergence of FeLV-C subgroups that specifically target erythroid progenitors [11, 14, 16]. The severity of anemia correlates with viral load and with the extent of bone marrow involvement [2]. Cats presenting with packed cell volumes below 15% at diagnosis have a particularly truncated survival, as this degree of anemia often reflects near-total erythroid aplasia.

Thrombocytopenia, identified in 56.6% of progressively infected cats in one large cross-sectional study, is similarly associated with adverse outcomes [3]. The mechanisms mirror those of anemia, including direct viral suppression of megakaryocytes, immune-mediated platelet destruction, and splenic sequestration. Clinically, severe thrombocytopenia predisposes to spontaneous hemorrhage, which can be rapidly fatal, particularly in the context of concurrent coagulopathies or neoplastic infiltration of critical organs. Lymphopenia, observed in 33.6% of progressive cases, is a direct reflection of FeLV's tropism for lymphoid tissues and its capacity to induce lymphocyte depletion [3]. This lymphopenia contributes to the profound immunosuppression that characterizes progressive infection, increasing susceptibility to secondary opportunistic infections that accelerate mortality [19, 33]. Importantly, the hematological profile can be dynamic: cats that maintain stable or improving red cell and platelet indices over serial monitoring carry a more favorable prognosis than those with progressive cytopenias [32]. Serial complete blood counts, therefore, are not merely diagnostic but serve as critical longitudinal prognostic tools.

Role of Co-Infections and Comorbid Conditions

Progressive FeLV infection rarely exists in isolation; the virus-induced immunosuppression creates a permissive environment for a wide array of secondary pathogens, each of which can independently worsen prognosis. Co-infection with feline immunodeficiency virus (FIV) is particularly consequential. In a study of 384 cats, FIV co-infection was 4.8 times more likely in the regressive group, but when co-infection occurs in the context of progressive FeLV, the compounded immunodeficiency accelerates clinical decline [3]. The odds of diagnosing bacterial diseases are significantly higher in cats co-infected with FeLV and FIV (OR 2.8), and the risk of viral diseases such as feline infectious peritonitis (FIP) is also elevated [33]. The synergistic pathological impact of FeLV and FIP co-infection was demonstrated in a case study where hematological examination revealed macrocytic hypochromic anemia, thrombocytopenia, and monocytosis, while serum biochemistry showed a decreased albumin-to-globulin ratio (0.39) and elevated hepatic enzymes, indicating combined hematological and hepatic dysfunction [52]. The presence of FIP in a progressively FeLV-infected cat carries an exceedingly grave prognosis, as the underlying immunosuppression impairs the host's ability to control coronavirus replication.

Co-infection with feline foamy virus (FFV) is associated with higher FeLV proviral loads and an increased likelihood of FeLV-B emergence, suggesting that FFV may modulate FeLV pathogenesis through immune perturbation [9, 38]. Mycoplasma haemofelis infection, detected in 33.3% of FeLV-positive cats in one Brazilian study, independently contributes to hemolytic anemia, compounding the already compromised erythron [25]. The clinical picture of multiple concurrent infections, viral, bacterial, and hemoparasitic, is a hallmark of terminal progressive FeLV infection and portends a survival time measured in days to weeks rather than months.

Host Genetic Factors and the Endogenous Retrovirus Paradox

A fascinating and increasingly recognized prognostic factor is the host's endogenous FeLV (enFeLV) burden. Research in a closed breeding colony revealed that higher enFeLV copy numbers were protective against progressive FeLV disease. Male cats had higher enFeLV copy numbers and were more likely to develop abortive infection, while females, with lower enFeLV copy numbers, were more prone to progressive disease and FeLV-B emergence [9]. The mechanistic underpinning of this protection is hypothesized to involve enFeLV-derived small interfering RNAs that interfere with exogenous FeLV replication. Transcriptional analysis has identified a 21-nucleotide microRNA transcribed from the enFeLV 5′-LTR that is expressed in lymphoid tissues, the primary sites of FeLV replication [26]. This endogenous siRNA may represent a natural RNA interference mechanism that constrains viral replication, and cats with higher enFeLV copy numbers may have a greater capacity to transcribe these protective RNAs, thereby slowing disease progression [26]. This finding also explains the sex-based disparity in FeLV outcomes, as the enFeLV elements are located on the X chromosome, and the higher copy number in males (XY) compared to females (XX) may confer a survival advantage [9]. Clinically, this suggests that male cats with progressive infection may, counterintuitively, have a slightly more favorable prognosis than their female counterparts, all else being equal.

Impact of Therapeutic Intervention on Survival

While no definitive cure exists for progressive FeLV infection, emerging data on antiretroviral therapy offer preliminary insights into prognostic modification. Raltegravir, an integrase inhibitor, has been evaluated in naturally infected cats with progressive FeLV and FeLV-related conditions. In a prospective study of 14 cats, the median survival time from FeLV diagnosis was 48 months, but from treatment initiation, a point at which cats were already clinically ill, the median survival was only 10.8 months [55]. This discrepancy underscores that raltegravir is instituted late in the disease course, when irreversible pathological changes have already occurred. The primary causes of death remained leukemia and lymphoma [55]. While raltegravir produced numerical reductions in plasma viral RNA (1.10 to 1.39 log₁₀ reductions at day 90), these did not reach statistical significance, and no consistent effect on proviral DNA was observed [55]. Importantly, most FeLV-related conditions remained clinically stable or improved during the 180-day monitoring period, suggesting that even modest viral suppression may palliate symptoms and extend survival in some cats [55]. The use of immunosuppressive therapy for specific complications, such as prednisolone for steroid-responsive neutropenia, can induce complete hematologic remission and prolonged survival in select cases, demonstrating that not all progressive infections are uniformly fatal and that targeted interventions can alter the clinical trajectory [47].

Risk Stratification and Clinical Decision-Making

Synthesizing the available evidence, a multidimensional risk stratification framework emerges. Cats diagnosed with progressive FeLV infection should be categorized based on: (1) viral load (high versus low proviral DNA and p27 antigen); (2) hematological profile (presence and severity of anemia, thrombocytopenia, and lymphopenia); (3) pathogenetic variant (myeloproliferative, myelosuppressive, dissociated, or subclinical); (4) presence of co-infections (FIV, FIP, hemoplasmas); and (5) clinical status at diagnosis (symptomatic versus asymptomatic). Cats with high viral loads, severe non-regenerative anemia (PCV < 15%), pancytopenia, concurrent FIV or FIP, and symptomatic presentation have a prognosis measured in weeks to a few months. In contrast, cats with low viral loads, stable hematological parameters, subclinical carrier state, and no complicating co-infections may survive for years with appropriate supportive care. The identification of wavy whiskers as a novel external sign of FeLV infection [34] may serve as an easily recognizable clinical clue prompting earlier diagnostic testing and, potentially, earlier intervention in the prognostic timeline. Ultimately, the prognosis in progressive FeLV infection is not fixed but is continuously re-evaluated through serial monitoring of viral and hematological parameters, allowing for dynamic risk assessment and tailored clinical management.

Pathophysiological Distinction Between Progressive and Regressive FeLV Infection

The divergence in clinical outcomes following exposure to Feline Leukemia Virus (FeLV) is fundamentally rooted in the complex interplay between viral replication kinetics and the host’s immune competence. This section dissects the pathophysiological mechanisms that differentiate progressive infection, characterized by persistent viremia, systemic dissemination, and lethal disease, from regressive infection, in which the host successfully restricts viral replication while maintaining a latent proviral reservoir. Understanding this distinction is paramount for clinical staging, prognostic accuracy, and therapeutic decision-making in feline practice.

The Hallmark of Progressive Infection: Unchecked Viral Replication and Systemic Dissemination

Progressive FeLV infection is defined by the host’s failure to contain viral replication following primary exposure. This outcome is most frequently observed in young, immunologically naïve, or immunocompromised cats [11, 27]. The pathophysiological cascade is initiated when FeLV, primarily subgroup A (FeLV-A), gains entry via the oronasal route and undergoes primary replication in local lymphoid tissues, notably the tonsils and pharyngeal lymph nodes [11, 19]. Within days to weeks, a primary cell-associated viremia disseminates the virus to systemic lymphoid organs, including the spleen, lymph nodes, and, critically, the bone marrow [11, 27]. The hallmark of progressive infection is the transition to a secondary, cell-free viremia, which is sustained indefinitely due to the failure of neutralizing antibody responses to clear circulating virions [13, 18].

The sustained high-level viremia in progressive infection has profound pathophysiological consequences. Quantitative analyses have demonstrated a strong positive correlation between FeLV p27 antigen concentration and proviral DNA load; samples with proviral loads exceeding 1 × 10⁶ copies/mL of whole blood consistently exhibit p27 antigen concentrations greater than 30 ng/mL, a threshold strongly associated with progressive disease [10]. This high viral burden leads to widespread infection of hematopoietic progenitor cells within the bone marrow stroma, a site that serves as a permanent viral reservoir. Studies using experimental infections have shown that cats with progressive infection exhibit a progressive and dramatic suppression of bone marrow fibroblast colony-forming units (CFU-F), often falling to 16–44% of pre-inoculation values within 2–10 weeks [14]. This stromal damage is directly mediated by the viral envelope protein p15E, which exerts a cytopathic effect on the hematopoietic microenvironment, thereby disrupting the niche required for normal hematopoiesis [14, 16]. The degree of stromal suppression varies by viral isolate; for instance, the Kawakami-Theilen (FeLV-KT) isolate induces more severe CFU-F suppression (38–70% of baseline) compared to the Rickard isolate (FeLV-R; 62–82%), correlating with the development of fatal non-regenerative anemia [16].

The relentless replication in the bone marrow culminates in a spectrum of hematologic abnormalities that are far more severe and prevalent in progressive versus regressive infection. Data from large cross-sectional studies demonstrate that cats with progressive infection exhibit significantly higher rates of thrombocytopenia (56.6% vs. 38.2%), non-regenerative anemia (32.8% vs. 23.5%), and lymphopenia (33.6% vs. 20.6%) compared to regressively infected animals [3]. Furthermore, median values for hemoglobin concentration, packed cell volume (PCV), platelet count, lymphocyte count, and eosinophil count are all significantly lower in the progressive group relative to both regressive and uninfected controls [3, 32]. A comprehensive retrospective analysis of bone marrow aspirates from progressive cats identified four distinct pathogenetic variants: a myeloproliferative variant (37.5% of cases) characterized by hyperleukocytosis and leukemia; a myelosuppressive variant (25%) manifesting as pancytopenia with myelodysplasia; a disassociated form (12.5%) with discordant viral replication between peripheral blood and bone marrow; and a subclinical carrier state (25%) with minimal peripheral blood changes despite bone marrow involvement [2]. This heterogeneity underscores the fact that even within the progressive category, the impact on the hematopoietic system can vary widely, depending on the viral subgroup, host genetics, and the presence of co-infections.

Beyond the bone marrow, progressive infection precipitates a state of profound immunosuppression. The virus directly infects and depletes CD4⁺ and CD8⁺ T lymphocytes, B cells, macrophages, and natural killer (NK) cells, while simultaneously disrupting the cytokine network required for effective humoral and cell-mediated immunity [19]. This immune dysregulation manifests as an increased susceptibility to secondary opportunistic infections, such as feline infectious peritonitis (FIP), hemoplasmosis, and sporotrichosis [15, 25, 52]. In a study of cats with sporotrichosis, those with progressive FeLV co-infection exhibited significantly higher levels of the immunosuppressive cytokine IL-10 and lower levels of IL-4 compared to retrovirus-negative cats, correlating with poorer general condition [15]. The oncogenic potential of the virus is also fully realized in progressive infection, driven by the integration of proviral DNA into the host genome, which can activate proto-oncogenes or disrupt tumor suppressor genes [19]. Consequently, the primary causes of death in progressively infected cats are neoplastic, lymphoma (38.5%) and leukemia (17.9%), followed by anemia (24.4%) and concurrent infections (15.4%) [1, 3]. The generation of recombinant FeLV-B subgroups through recombination with endogenous FeLV (enFeLV) sequences is also more common in progressive infection, and these variants are associated with a higher risk of lymphoma and leukemia [4, 9, 24]. The median survival time for cats diagnosed with progressive infection is tragically short, reported as 30 days in one large Brazilian cohort, with a 4–5-fold increase in the hazard ratio for death compared to regressive or uninfected cats [1].

The Regressive Paradigm: Immune-Mediated Containment and Latent Proviral Persistence

In stark contrast, regressive FeLV infection represents a successful, albeit non-sterilizing, host immune response. Following initial viral exposure, cats that will develop a regressive outcome mount a rapid and effective neutralizing antibody response that clears cell-free viremia and prevents the establishment of sustained antigenemia [11, 13, 18]. These cats may experience a transient, low-level antigenemia that is quickly resolved, or they may never become p27 antigen-positive in peripheral blood using standard ELISA tests [13, 27]. Despite the clearance of productive viral replication, proviral DNA persists at low levels, integrated into the genome of hematopoietic stem cells within the bone marrow and other lymphoid tissues [8, 12, 27].

The pathophysiological hallmark of regressive infection is the maintenance of a delicate equilibrium between the host immune system and the latent proviral reservoir. The host’s immune surveillance, particularly by cytotoxic T lymphocytes and neutralizing antibodies, keeps the virus in a state of transcriptional latency, preventing reactivation and renewed viral shedding [27, 49]. The proviral DNA load in the blood of regressively infected cats is typically ≤4.0 × 10⁵ copies/mL, a threshold that is often undetectable by point-of-care antigen tests but is readily identifiable by sensitive quantitative PCR (qPCR) assays [6, 10]. This low proviral burden has significant clinical implications. Hematologic abnormalities, while present, are substantially milder than in progressive infection. Data from the same cross-sectional study mentioned previously show that although regressive cats have lower median values for PCV, hemoglobin, and platelets compared to uninfected controls, these parameters are significantly higher than those observed in progressive cats [3]. The prevalence of specific cytopenias is also lower: non-regenerative anemia (23.5%), thrombocytopenia (38.2%), and lymphopenia (20.6%) [3].

Crucially, regressive infection does not typically result in the same degree of bone marrow stromal damage or profound immunosuppression seen in progressive disease. While a transient suppression of CFU-F has been documented at two weeks post-inoculation, this suppression resolves by week four, and regressor cats do not develop the persistent, progressive stromal dysfunction characteristic of progressors [14]. Accordingly, regressive cats are generally not at increased risk for opportunistic infections or the full spectrum of FeLV-associated diseases. A large survival analysis confirmed that regressive infection had no direct impact on the survival curve; the median survival time for the regressive group was not reached during the study period (12–54 months), in stark contrast to the 30-day median for progressive cats [1]. This suggests that the long-term life expectancy of a cat with regressive FeLV is essentially normal, provided that the infection remains in this controlled state.

However, the latent proviral reservoir is not biologically inert. While most cats remain asymptomatic, there is a documented risk of viral reactivation, particularly under conditions of immunosuppression (e.g., from corticosteroid therapy, concurrent disease, or stress) [12, 27]. The biological significance of these provirus carriers was starkly demonstrated in a landmark transfusion study, where blood from aviremic, provirus-positive (regressive) donors was transfused into naïve recipient cats. This resulted in active FeLV infection in all recipients, with some developing progressive outcomes and fatal FeLV-associated diseases, including T-cell lymphoma and non-regenerative anemia due to FeLV-C emergence [12]. This finding underscores that regressive cats are not cured; they remain lifelong carriers of replication-competent provirus that can be horizontally transmitted via blood transfusion and, potentially, through other routes. Furthermore, there is increasing evidence that regressive infection may contribute to the development of lymphoma. A 2025 review of Australian and New Zealand guidelines notes that proviral DNA has been detected in lymphomas of regressively infected cats, suggesting that even in the absence of active viremia, the integrated provirus may exert a low-level oncogenic effect, though the absolute risk appears much lower than in progressive infection [43].

Comparative Long-Term Outcomes: Neoplastic Risk and Clinical Management

The pathophysiological divergence between progressive and regressive infection dictates vastly different clinical trajectories. For the progressively infected cat, the path is one of inexorable decline. The high viral load fuels continuous hematopoietic destruction, immune exhaustion, and a high incidence of neoplastic transformation. The odds of developing lymphoma are 3.9 times higher, and leukemia 19.4 times higher, in FeLV-infected cats compared to uninfected controls [33]. The emergence of recombinant subgroups, particularly FeLV-B and FeLV-C, further accelerates disease, with FeLV-C being specifically associated with a severe, fatal aplastic anemia [4, 12].

For the regressively infected cat, the prognosis is markedly better. They can live for years without any FeLV-related clinical signs [1, 42]. However, they require vigilant monitoring. The primary long-term concerns are two-fold: first, the risk of reactivation, which, while low, can occur under immunosuppressive duress; and second, a potentially elevated, albeit low, risk of lymphoma [43]. Epidemiological data from a 10-year study in southern Italy found that 7.64% of cats were FeLV antigen-positive (indicating progressive infection), but the prevalence of provirus-positive, antigen-negative (regressive) cats was not negligible [29]. These cats represent a hidden reservoir that can perpetuate FeLV transmission within a population, particularly in multi-cat households or shelters. The clinical management of regressively infected cats therefore focuses on minimizing stress, providing high-quality nutrition, avoiding unnecessary immunosuppressive therapies, and maintaining regular veterinary check-ups to detect early signs of reactivation or neoplastic disease. In contrast, the management of progressive infection is palliative, focusing on managing secondary infections, controlling clinical signs, and considering experimental antiviral therapies, though their efficacy remains variable [55].

In summary, the pathophysiological distinction between progressive and regressive FeLV infection lies in the host’s ability to mount an effective, sustained immune response that shifts the virus from a state of active replication and systemic spread to one of immunologic latency and low-level proviral persistence. This distinction is not merely academic but is the primary determinant of survival, clinical presentation, and management strategy for infected cats. As recognized by the World Organisation for Animal Health (WOAH) and the CDC, understanding these divergent outcomes is crucial for implementing effective surveillance, prevention, and control programs for this globally important feline pathogen.

References

[1] Biezus G, Cristo TGd, Koehler CMF, Kaveski FYdQ, Miranda TSV, Ferian PE, et al.. Survival analysis and clinical abnormalities in cats with progressive or regressive feline leukemia virus (FeLV) infection in Brazil. PLoS ONE. 2025. DOI: https://doi.org/10.1371/journal.pone.0322691

[2] Tsarkova KN, Zaberezhny A, Bogomolova O, Kuryndina AS, Polyakova I. Spectrum of hematological abnormalities in progressive feline leukemia virus infection: data from a comprehensive examination with bone marrow aspiration and PCR diagnostics. Veterinariya, Zootekhniya i Biotekhnologiya. 2025. DOI: https://doi.org/10.36871/vet.zoo.bio.202511307

[3] Biezus G, Cristo TGd, Casa MdS, Lovatel M, Vavassori M, Teixeira MBdS, et al.. Progressive and regressive infection with feline leukemia virus (FeLV) in cats in southern Brazil: Prevalence, risk factors associated, clinical and hematologic alterations.. Preventive Veterinary Medicine. 2023. DOI: https://doi.org/10.1016/j.prevetmed.2023.105945

[4] Biezus G, Cristo TGd, Neves GBd, Casa MdS, Brizola PB, Sombrio MS, et al.. Phylogenetic identification of feline leukemia virus A and B in cats with progressive infection developing into lymphoma and leukemia. Virus Research. 2023. DOI: https://doi.org/10.1016/j.virusres.2023.199093

[5] O. P, O. T, M S, M S, V. G, T. M. Feline leukemia virus: etiologic, pathogenetic and epidemiologic aspects of infection in Europe (review article). Bulletin "Veterinary biotechnology". 2025. DOI: https://doi.org/10.31073/vet_biotech46-07

[6] Almeida PMd, Belas A, Bragança M, Oliveira JDd, Viegas C. Prevalence and genetic characterization of feline leukemia virus in portuguese stray cats. BMC Veterinary Research. 2025. DOI: https://doi.org/10.1186/s12917-025-04691-2

[7] Diesel LP, Mello LDd, Santana WdO, Ikuta N, Fonseca A, Kipper D, et al.. Epidemiological Insights into Feline Leukemia Virus Infections in an Urban Cat (Felis catus) Population from Brazil. Animals. 2024. DOI: https://doi.org/10.3390/ani14071051

[8] Tsarkova KN, Bogomolova O. Feline viral leukemia: unresolved problems in the diagnosis of latent infection. БИОТЕХНОЛОГИЯ: НАУЧНЫЕ ИССЛЕДОВАНИЯ И СВЯЗЬ С ПРОИЗВОДСТВОМ. 2025. DOI: https://doi.org/10.47804/978-5-89904-039-9-2025-22

[9] Powers JA, Chiu E, Kraberger S, Roelke-Parker M, Lowery I, Erbeck K, et al.. Feline Leukemia Virus (FeLV) Disease Outcomes in a Domestic Cat Breeding Colony: Relationship to Endogenous FeLV and Other Chronic Viral Infections. Journal of Virology. 2018. DOI: https://doi.org/10.1128/JVI.00649-18

[10] Beall M, Buch J, Cahill R, Clark GH, Hanscom JL, Estrada M, et al.. Evaluation of a quantitative enzyme-linked immunosorbent assay for feline leukemia virus p27 antigen and comparison to proviral DNA loads by real-time polymerase chain reaction.. Comparative Immunology, Microbiology & Infectious Diseases. 2019. DOI: https://doi.org/10.1016/j.cimid.2019.101348

[11] Hoover E, Mullins JI. Feline leukemia virus infection and diseases.. Journal of the American Veterinary Medical Association. 1991. DOI: https://doi.org/10.2460/javma.1991.199.10.1287

[12] Nesina S, Helfer-Hungerbuehler AK, Riond B, Boretti F, Willi B, Meli M, et al.. Retroviral DNA, the silent winner: blood transfusion containing latent feline leukemia provirus causes infection and disease in naïve recipient cats. Retrovirology. 2015. DOI: https://doi.org/10.1186/s12977-015-0231-z

[13] Torres AN, Mathiason C, Hoover E. Re-examination of feline leukemia virus: host relationships using real-time PCR.. Virology. 2005. DOI: https://doi.org/10.1016/J.VIROL.2004.10.050

[14] Wellman ML, Kociba G, Mathes LE, Olsen RG. Suppression of feline bone marrow fibroblast colony-forming units by feline leukemia virus.. American Journal of Veterinary Research. 1988. DOI: https://doi.org/10.2460/ajvr.1988.49.02.227

[15] Miranda LDd, Meli M, Conceição-Silva F, Novacco M, Menezes R, Pereira S, et al.. Co-infection with feline retrovirus is related to changes in immunological parameters of cats with sporotrichosis. PLoS ONE. 2018. DOI: https://doi.org/10.1371/journal.pone.0207644

[16] Wellman ML, Kociba G, Mathes L. Variable suppression of feline bone marrow fibroblast colony-forming units by two isolates of feline leukemia virus.. American Journal of Veterinary Research. 1991. DOI: https://doi.org/10.2460/ajvr.1991.52.11.1924

[17] Essex M, Cotter S, Carpenter JL. Feline virus-induced tumors and the immune response: recent developments.. American Journal of Veterinary Research. 1973. DOI: https://doi.org/10.2460/ajvr.1973.34.06.809

[18] Major A, Cattori V, Boenzli E, Riond B, Ossent P, Meli M, et al.. Exposure of cats to low doses of FeLV: seroconversion as the sole parameter of infection. Veterinary Research. 2009. DOI: https://doi.org/10.1051/vetres/2009065

[19] Romanishina ТО, Lakhman A, Behas V, Feshchenko D. Feline Leukemia Virus Infection (FeLV): Review of Pathogenesis and Host-Oriented Mechanisms of Virus-Induced Immunosuppression. Scientific Messenger of LNU of Veterinary Medicine and Biotechnologies. 2025. DOI: https://doi.org/10.32718/nvlvet12008

[20] Meli M, Pineroli B, Geisser E, Hofmann-Lehmann R. Prospective Investigation of Feline Leukemia Virus Infection in Stray Cats Subjected to a Trap–Neuter–Return Program in Switzerland. Viruses. 2024. DOI: https://doi.org/10.3390/v16030394

[21] Castillo-Aliaga C, Castro-Seriche S, Jerez-Morales A, Tarlinton R. High prevalence and risk factors of feline leukemia virus infection in Chilean urban cats (Felis catus).. Research in Veterinary Science. 2024. DOI: https://doi.org/10.1016/j.rvsc.2024.105403

[22] Almeida PMd, Belas A, Nogueira P, Meneses A, Oliveira JDd, Viegas C. Prevalence of feline leukemia virus infection and associated diseases in a Portuguese domestic cat population: A 4.5-year cross-sectional study. PLoS ONE. 2026. DOI: https://doi.org/10.1371/journal.pone.0339172

[23] Sprißler F, Jongwattanapisan P, Luengyosluechakul S, Pusoonthornthum R, Reese S, Bergmann M, et al.. Prevalence and Risk Factors of Feline Immunodeficiency Virus and Feline Leukemia Virus Infection in Healthy Cats in Thailand. Frontiers in Veterinary Science. 2022. DOI: https://doi.org/10.3389/fvets.2021.764217

[24] Erbeck K, Gagne R, Kraberger S, Chiu E, Roelke-Parker M, Vandewoude S. Feline Leukemia Virus (FeLV) Endogenous and Exogenous Recombination Events Result in Multiple FeLV-B Subtypes during Natural Infection. bioRxiv. 2021. DOI: https://doi.org/10.1128/JVI.00353-21

[25] Maciel AdR, Biezus G, Cristo TGd, Miletti L, Maciel UdC, Medeiros AL, et al.. Mycoplasma haemofelis infection and its correlation with feline leukemia virus (FeLV) and feline immunodeficiency virus (FIV) in cats in Southern Brazil.. Comparative Immunology, Microbiology & Infectious Diseases. 2022. DOI: https://doi.org/10.1016/j.cimid.2022.101941

[26] Chiu E, McDonald CA, Vandewoude S. Endogenous Feline Leukemia Virus (FeLV) siRNA Transcription May Interfere with Exogenous FeLV Infection. bioRxiv. 2021. DOI: https://doi.org/10.1128/JVI.00070-21

[27] Hartmann K, Hofmann-Lehmann R. What's New in Feline Leukemia Virus Infection.. The Veterinary clinics of North America. Small animal practice. 2020. DOI: https://doi.org/10.1016/j.cvsm.2020.05.006

[28] Russo V, Roperto F, Taulescu M, Falco FD, Urraro C, Corrado F, et al.. Expression of the feline leukemia virus subgroup C receptors in normal and neoplastic urothelium of the urinary bladder of cattle associated with bovine papillomavirus infection.. Veterinary Microbiology. 2019. DOI: https://doi.org/10.1016/j.vetmic.2018.12.024

[29] Fusco G, Marati L, Pugliese A, Levante M, Ferrara G, Carlo Ed, et al.. Prevalence of feline leukemia virus and feline immunodeficiency virus in cats from southern Italy: a 10-year cross-sectional study. Frontiers in Veterinary Science. 2023. DOI: https://doi.org/10.3389/fvets.2023.1260081

[30] Terry A, Kilbey A, Naseer A, Levy L, Ahmad S, Watts C, et al.. Barriers to Infection of Human Cells by Feline Leukemia Virus: Insights into Resistance to Zoonosis. Journal of Virology. 2016. DOI: https://doi.org/10.1128/JVI.02119-16

[31] Giselbrecht J, Jähne S, Bergmann M, Meli M, Pineroli B, Boenzli E, et al.. Prevalence of Different Courses of Feline Leukaemia Virus Infection in Four European Countries. Viruses. 2023. DOI: https://doi.org/10.3390/v15081718

[32] Biezus G, Ferian PE, Pereira L, Withoeft J, Antunes MM, Xavier MGN, et al.. Clinical and Haematological Disorders in Cats with Natural and Progressive Infection by Feline Leukemia Virus (FeLV). Acta Scientiae Veterinariae. 2019. DOI: https://doi.org/10.22456/1679-9216.90027

[33] Mello LDd, Ribeiro PR, Almeida BAd, Bandinelli M, Sonne L, Driemeier D, et al.. Diseases associated with feline leukemia virus and feline immunodeficiency virus infection: A retrospective study of 1470 necropsied cats (2010-2020).. Comparative Immunology, Microbiology & Infectious Diseases. 2023. DOI: https://doi.org/10.1016/j.cimid.2023.101963

[34] Morishita M, Sunden Y, Horiguchi M, Sakoya H, Yokogawa M, Ino H, et al.. Wavy changes in the whiskers of domestic cats are correlated with feline leukemia virus infection. BMC Veterinary Research. 2023. DOI: https://doi.org/10.1186/s12917-023-03610-7

[35] He M, Feng S, Shi K, Shi Y, Long F, Yin Y, et al.. One-step triplex TaqMan quantitative reverse transcription polymerase chain reaction for the detection of feline coronavirus, feline panleukopenia virus, and feline leukemia virus. Veterinary World. 2024. DOI: https://doi.org/10.14202/vetworld.2024.946-955

[36] Moll G, Swenson C, Yuzbasiyan-Gurkan V. BET Inhibitor JQ1 Attenuates Feline Leukemia Virus DNA, Provirus, and Antigen Production in Domestic Cat Cell Lines. Viruses. 2023. DOI: https://doi.org/10.3390/v15091853

[37] Filoni C, Helfer-Hungerbuehler AK, Catão-Dias J, Marques M, Torres L, Reinacher M, et al.. Putative progressive and abortive feline leukemia virus infection outcomes in captive jaguarundis (Puma yagouaroundi). Virology Journal. 2017. DOI: https://doi.org/10.1186/s12985-017-0889-z

[38] Cavalcante LTF, Muniz CP, Jia H, Augusto A, Troccoli F, Medeiros SO, et al.. Clinical and Molecular Features of Feline Foamy Virus and Feline Leukemia Virus Co-Infection in Naturally-Infected Cats. Viruses. 2018. DOI: https://doi.org/10.3390/v10120702

[39] Lacharoje S, Techangamsuwan S, Chaichanawongsaroj N. Rapid characterization of feline leukemia virus infective stages by a novel nested recombinase polymerase amplification (RPA) and reverse transcriptase-RPA. Scientific Reports. 2021. DOI: https://doi.org/10.1038/s41598-021-01585-9

[40] Capozza P, Lorusso E, Colella V, Thibault J, Tan D, Tronel J, et al.. Feline leukemia virus in owned cats in Southeast Asia and Taiwan.. Veterinary Microbiology. 2021. DOI: https://doi.org/10.1016/j.vetmic.2021.109008

[41] Figueiredo A, Júnior JPA. Vírus da leucemia felina: análise da classificação da infecção, das técnicas de diagnóstico e da eficácia da vacinação com o emprego de técnicas sensíveis de detecção viral. Ciencia Rural. 2011. DOI: https://doi.org/10.1590/S0103-84782011001100017

[42] Beall M, Moore D, Turner S, Levy JK. Feline leukemia virus lifetime study: whole blood samples increase detection of low positive cats with extended long-term survival. Journal of feline medicine and surgery. 2025. DOI: https://doi.org/10.1177/1098612X251379219

[43] Westman M, Coggins S, Dorsselaer Mv, Norris J, Squires R, Thompson M, et al.. Feline leukaemia virus (FeLV) infection in domestic pet cats in Australia and New Zealand: Guidelines for diagnosis, prevention and management. Australian Veterinary Journal. 2025. DOI: https://doi.org/10.1111/avj.13470

[44] Nájera F, López G, Rey-Wamba Td, Malik RA, Garrote G, López-Parra M, et al.. Long-term surveillance of the feline leukemia virus in the endangered Iberian lynx (Lynx pardinus) in Andalusia, Spain (2008–2021). Scientific Reports. 2024. DOI: https://doi.org/10.1038/s41598-024-55847-3

[45] Rudan N, Marković E, Kučer N. Evaluation of clinical and haematological parameters in differentiation of feline immunodeficiency and feline leukemia virus infection. Veterinarski Arhiv. 2017. DOI: https://doi.org/10.24099/VET.ARHIV.160525

[46] Gregor KM, Mirolo M, Brandes F, Jesse ST, Kaiser F, Verspohl J, et al.. Fatal Feline Leukemia Virus-Associated Enteritis in a Wild Eurasian Lynx (Lynx lynx) in Germany. Biology. 2024. DOI: https://doi.org/10.3390/biology13120997

[47] Stavroulaki EM, Mylonakis M, Papanikolaou E, Hatzis A, Xenoulis P. Steroid-responsive neutropenia in a cat with progressive feline leukemia virus infection.. Veterinary clinical pathology. 2020. DOI: https://doi.org/10.1111/vcp.12896

[48] Westman ME, Giselbrecht J, Norris J, Malik R, Green J, Burton-Bradley E, et al.. Field Performance of a Rapid Test to Detect Progressive, Regressive, and Abortive Feline Leukemia Virus Infections in Domestic Cats in Australia and Germany. Viruses. 2023. DOI: https://doi.org/10.3390/v15020491

[49] Helfer-Hungerbuehler AK, Shah J, Meili T, Boenzli E, Li P, Hofmann-Lehmann R. Adeno-Associated Vector-Delivered CRISPR/SaCas9 System Reduces Feline Leukemia Virus Production In Vitro. Viruses. 2021. DOI: https://doi.org/10.3390/v13081636

[50] Liu J, O'connor T, Beall M, Chandrashekar R, Lappin M. Evaluation of rapid diagnostic test kits for feline leukemia virus infection using samples from naturally infected cats. JFMS open reports. 2016. DOI: https://doi.org/10.1177/2055116916667757

[51] Singh S, Davenport KA, Schooley E, Ruggiero A, Nassar S, Buch J, et al.. Diagnostic Accuracy of a Point-of-Care Immunoassay for Feline Immunodeficiency Virus Antibodies, Feline Leukemia Virus Antigen, and Dirofilaria immitis Antigen. Viruses. 2023. DOI: https://doi.org/10.3390/v15102117

[52] Maharani S, Dani RN, Dara RSA, Jannah AN. Feline infectious peritonitis and feline leukemia virus co-infection: a case study on diagnostic and clinical pathological findings. ARSHI Veterinary Letters. 2025. DOI: https://doi.org/10.29244/avl.9.1.15-16

[53] Biezus G, Cristo TGd, Schade MFdS, Ferian PE, Carniel F, Miletti L, et al.. Plasma cell pododermatitis associated with feline leukemia virus (FeLV) and concomitant feline immunodeficiency virus (FIV) infection in a cat.. Topics in Companion Animal Medicine. 2020. DOI: https://doi.org/10.1016/j.tcam.2020.100475

[54] Pardo A, Gómez M, González C. Cerebellar cortical degeneration associated with feline leukemia virus infection and cerebellar lymphoma in a young cat. Open Veterinary Journal. 2019. DOI: https://doi.org/10.4314/ovj.v9i3.9

[55] Almeida PMd, Belas A, Martins JM, Picado R, Meneses A, Oliveira JTTd, et al.. EXPRESS: Clinical and virological effects of the integrase inhibitor raltegravir in cats with naturally progressive feline leukaemia virus infection. Journal of feline medicine and surgery. 2026. DOI: https://doi.org/10.1177/1098612x261452556